The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | PET-CT findings have prognostic value in NDMM
Philippe Moreau, MD, University Hospital Hôtel-Dieu, Nantes, France, discusses the results of the CASSIOPET study. This study evaluated the prognostic value of positron emission tomography-computed tomography (PET-CT) at diagnosis and follow-up in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients treated in the phase III CASSIOPEIA trial (NCT02541383). Results show that baseline PET-CT negativity is associated with a better outcome. Additionally, Prof. Moreau reveals that daratumumab improves the outcome of baseline PET-CT negative and positive patients. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
